Total Funding
6
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
466783
Kanyos Bio was founded with the goal of developing antigen-specific immune tolerance technology for two specific autoimmune indications.
Acquired by 
Anokion
Stephan Kontos: Co-Founder
About the Company
Kanyos Bio was founded with the goal of developing antigen-specific immune tolerance technology for two specific autoimmune indications, type-1 diabetes and celiac disease.
Our technology originated at EPFL (Ecole Polytechnique Fédérale Lausanne) in Switzerland with our sister company, Anokion. Kanyos and Anokion are collaborating in this
effort with Astellas Pharma, Inc. (“Astellas”). As an independent affiliate, Kanyos aims to develop antigen-specific, disease-modifying therapies for patients with type-1 diabetes and celiac disease by leveraging the immunotechnology expertise of Anokion and the clinical translation experience of Astellas.
Women Founded
